

A Look at *Retinoblastoma*



1 in
15–20k
live births


No sex or ethnic
predisposition

<5
years old

Median diagnosis
age — 2 years


01 INTRODUCTION

WHAT?




- Malignant tumour of developing retinal cells
- Primarily affects infants and young children
- Caused by loss of RB1 tumour suppressor gene^{1,2}

WHY?



- RB1 controls cell cycle via pRB^{1,2}
- Cancer when both copies inactivated
- Based on Knudson's Two-Hit Hypothesis

WHO AND WHERE?



- Unilateral → somatic mutation³
- Bilateral → germline mutation
- Most common intraocular cancer in children
- Worse outcomes in low-income countries⁴

02 ETIOLOGY OF RETINOBLASTOMA

RB1 Gene · tumour suppressor

The RB1 gene encodes **pRB**, an E2F inhibitor blocking the **G1→S phase** transition. Loss of both copies → **uncontrolled proliferation**.⁵


- 13q14 deletion removes one RB1 allele — only one more hit needed to fully lose RB1^{6,7}

Knudson's Two-Hit Model^{7,8}

Type	Hit 1	Hit 2	Onset	Side
Hereditary	Germline	Somatic	Early	Bilateral
Sporadic	Somatic	Somatic	Later	Unilateral

Systemic Cancer Risk · hereditary only

- Germline RB1 = body-wide susceptibility, not just the eye⁹
- Risk of osteosarcoma, melanoma, pineal tumours
- Sporadic mutations localised to retinal cell of origin



03 PATHOPHYSIOLOGY

Retinal cone precursor cells have weaker compensatory tumour-suppressor pathways, making them particularly susceptible to malignant transformation when RB1 is lost.^{10,11}

Tumour Growth Patterns

RT-1 · Focal Single mass, sharp border. Normal retina preserved.¹³




RT-2 · Expansive Large abnormal zones; microtumours in adjacent retina.¹³



RT-3 · Diffuse Entire retina involved. Ciliary body and iris affected.¹³




Progression: If left untreated, the tumour invades local structures, seeds new foci, and eventually spreads beyond the eye.¹²



04 CLINICAL PRESENTATION

Common Signs

- Leukocoria (white pupillary reflex) — most classic sign
- Strabismus — misaligned eyes due to vision loss^{14,15}
- Persistent red eye, uveitis-like inflammation
- Hyphema, pseudohypopyon, iris heterochromia
- Secondary glaucoma, orbital swelling / proptosis¹⁴



Red Flags — refer immediately

- Leukocoria in photos or clinical exam
- Persistent strabismus or abnormal red reflex
- Unexplained vision loss in child under 5
- Persistent red, painful eye or eye hyphema¹⁵

15


05 DIAGNOSIS & SCREENING

Primary method: Ophthalmologic exam under anaesthesia using fundoscopy to directly visualise retinal tumours. Imaging supports staging, spread assessment, and prognosis.¹⁵

Supporting Diagnostics


Imaging

MRI for optic nerve & brain spread. Ultrasound detects masses. OCT for small tumours & monitoring.¹⁵




Genetic (RB1) Testing

Blood & tumour analysis identifies hereditary vs sporadic. Assesses family risk for genetic counselling.¹⁵



Screening

Children with family history undergo regular dilated eye exams from birth to detect early disease.¹⁶




06 TREATMENT OPTIONS

Treatment selection — based on disease stage

Small / focal focal therapy ± chemo ¹⁸	Moderate / bilateral IVC or IAC + focal ¹⁸	Advanced intraocular enucleation ± adj. chemo ¹⁸	Metastatic / CNS HD chemo + radiotherapy ¹⁸
--	--	--	---


Focal Therapies

Locally target the tumour while preserving surrounding tissue. Used for small, localised lesions, often combined with chemotherapy.¹⁸




Intra-Arterial Chemo (IAC)

Catheter delivers chemo directly to the ophthalmic artery — 10× higher dose to the eye vs IVC. Preferred for unilateral disease. Superior globe-salvage rates.¹⁹



Intravenous Chemo (IVC)

Systemic multi-drug regimen via bloodstream. Shrinks tumours before focal therapy. Also used adjuvantly post-surgery.¹⁹




Radiation (EBRT)

High-energy radiation for extraocular spread or orbital involvement. ≥45 Gy orbital / craniospinal. Now less common due to long-term risks in children.¹⁸



Enucleation · Last Resort

Surgical removal of the affected eye. Reserved for advanced Group E tumours, failed globe-salvage attempts, or extraocular spread. Major centres have dramatically reduced enucleation rates over the last 30 years in favour of globe-salvaging techniques. Allows histopathologic confirmation and is lifesaving when other options fail.¹⁸



Treatment often involves a multidisciplinary team, including ophthalmologists, radiologists, pathologists, and oncologists.¹⁸

95%
survival rate

High-income countries with
early treatment

~30%
without access to care

~90%
globe salvage

Eye preserved with modern IAC
when treated early

2–3
years earlier diagnosis

High-income vs low-income
countries

References:

